Literature DB >> 3948314

Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles.

N W Gibson, J Hartley, R J La France, K Vaughan.   

Abstract

A series of alkyltriazenylimidazoles have been investigated for their differential cytotoxicity towards the HT-29 (Mer+) and BE (Mer-) cell lines and for their ability to cause DNA strand breaks and cross-links. A monomethyltriazene, and some hydroxymethyltriazene derivatives capable of generating the monomethyltriazene in situ, were preferentially cytotoxic towards the BE cell line compared with the HT-29 cell line, with very close similarity in the differential toxicity to the analogous monochloroethyltriazene. In contrast, the dimethyl- and monoethyltriazenes in the series display reduced toxicity towards the BE cell line with little or no differential toxicity between BE and HT-29 cell lines. With another pair of human cell lines, the IMR-90 (Mer+) and VA-13 (Mer-) cells, the monomethyl- and monochloroethyltriazenes were again more cytotoxic to the Mer- cells. Neither the formation of DNA single-strand breaks or DNA-protein cross-links could account for the differential cytotoxicity observed in the Mer+ and Mer- cells. More importantly, the inability of the monofunctional monomethyltriazene to cross-link DNA tends to question the role of DNA inter-strand cross-linking as a mechanism for cell killing by chloroethylating agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948314     DOI: 10.1093/carcin/7.2.259

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

Authors:  C Dive; P Workman; J V Watson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  R B Mitchell; M E Dolan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro.

Authors:  B J Jean-Claude; A Mustafa; N D Cetateanu; Z Damian; J De Marte; R Yen; D Vasilescu; T H Chan; B Leyland-Jones
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.

Authors:  R Banerjee; Z Rachid; Q Qiu; J P McNamee; A M Tari; B J Jean-Claude
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

6.  Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Authors:  S M Lee; N Thatcher; M Dougal; G P Margison
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

7.  Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.

Authors:  S A Kyrtopoulos; V L Souliotis; C Valavanis; V A Boussiotis; G A Pangalis
Journal:  Environ Health Perspect       Date:  1993-03       Impact factor: 9.031

8.  Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.

Authors:  J M Lunn; A L Harris
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

9.  Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.

Authors:  B J Foster; D R Newell; J Carmichael; A L Harris; L A Gumbrell; M Jones; P M Goodard; A H Calvert
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.